Discover the pivotal insights from a single-center study in India on the impact of de novo donor-specific anti-human leukocyte antigen antibodies on the outcomes of pediatric renal transplant recipients.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
De novo Donor-specific Anti-human Leukocyte Antigen Antibody and Its Outcome in Pediatric Renal Transplant Recipients: A Single-center Experience in India.
Saha et al., Saudi J Kidney Dis Transpl 2023
DOI: 10.4103/1319-2442.391006
Oh, the Wonders of Hindsight: A Tale of Antibodies and Kidney Grafts in Indian Children
Once upon a time, a group of researchers decided to take a stroll down memory lane, looking back at the good old days between November 2016 and October 2019. They were particularly interested in the adventurous journey of kidney transplants in children in India, and more specifically, the thrilling appearance of de novo donor-specific anti-HLA antibodies (dnDSA). Because, you know, there’s nothing quite like a surprise immune response to keep things interesting.
They gathered their magical tools: complement-dependent cytotoxicity, flow cytometry crossmatch, and the ever-so-flashy single antigen bead (SAB) test. With these, they could spot those pesky DSAs that just love to crash the transplant party. The kids in the study were given the usual cocktail of immunosuppressants, because why mess with tradition?
Now, here’s the kicker: they checked for these uninvited antibodies at the most predictable times – 1, 3, 6 months, and then yearly for the lucky seven, and only when the graft was throwing a fit for the other eight. And if the antibodies glowed with a mean fluorescence intensity of ≥1000, it was party time (for the researchers, not the graft).
Out of the fifteen all-star boys, with a median age of 13 (because who needs girls in studies, right?), a whopping 53% developed dnDSA. It’s like half the kids decided to join the antibody rave. Most of these antibodies were the cool Class II type, with a few dabbling in Class I, and some couldn’t decide and went for both. The antibodies had a preference for DQ and DR, because who doesn’t love a good alphabet soup?
And surprise, surprise, all the kids with these antibodies had antibody-mediated rejection (ABMR). It’s almost as if there’s a connection there! Some of these rejections were sneaky and subclinical, because who doesn’t love a good plot twist? Despite throwing the kitchen sink at them, these antibodies were stubborn and stuck around, though the grafts did get a bit better.
As expected, the kids with DSA and ABMR had worse graft function than the antibody-free club. So, the moral of the story? The proportion of dnDSA was alarmingly high, and it seems like early detection and treatment of ABMR is the way to go. But hey, who would’ve thought that monitoring for antibodies could help with early diagnosis and treatment? Oh, right, probably everyone.
And they all lived moderately ever after, with a little less kidney function and a lot more antibodies.